RA
ALDX icon

Rovida Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Rovida Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-130,000
Closed -$1.54M – 48
2021
Q1 		$1.54M Buy
+130,000
New +$1.5M 0.07% 44

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Rovida Advisors's ALDX Position: Q2 2021 in Review

Rovida Advisors sold out of Aldeyra Therapeutics (ALDX) in Q2 2021, closing a stake of 130,000 shares — an estimated $1.54M sold.

Rovida Advisors first reported a position in ALDX in Q1 2021 and held it in 1 quarter. The position peaked at $1.54M in Q1 2021. 136 funds tracked by Wall St. Rank hold ALDX as of Q2 2021.

  • Rovida Advisors reported no remaining Aldeyra Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Rovida Advisors sold 130,000 Aldeyra Therapeutics shares in Q2 2021, an estimated $1.54M.
  • Rovida Advisors first reported a position in Aldeyra Therapeutics in Q1 2021 and held it in 1 quarter.
  • Rovida Advisors's Aldeyra Therapeutics position peaked at $1.54M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2021.

Based on Rovida Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.